Literature DB >> 61585

Propranolol in the treatment of thyrotoxicosis: a review.

D G McDevitt.   

Abstract

The clinical manifestations of hyperthyroidism have suggested to physicians for many years that the sympathetic nervous system may be involved in their production. Despite this, the precise interrelationship between the thyroid gland and the sympathetic nervous system has never been defined but controlled investigations have shown that hypersensitivity to catcholamines does not occur in animals or man with artificially produced thyrotoxicosis. In recent years beta-adrenoceptor blocking drugs, and in particular propranolol, have been used in patients with hyperthyroidism. Evidence exists that they control some of the peripheral manifestations of the disease, including nervousness, palpitations, tachycardia, increased cardiac output and tremor, but they do not appear to affect the underlying thyrotoxic process itself. Propranolol has been used with sucess in the treatment of acute hyperthyroid crisis, in pre-operative preparations for thyroidectomy, for the control of symptoms and signs following the administration of radioactive iodine therapy and antithyroid drugs, during the period of diagnostic thyroid investigations and occasionally as the sole therapy. The supportive role of propranolol in the management of hyperthyroidism is now established and in some instances such as radioactive iodine therapy, it has enabled improvements in the existing methods of treatment to be achieved.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 61585

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  9 in total

Review 1.  Influence of thyroid dysfunction on drug pharmacokinetics.

Authors:  G M Shenfield
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

2.  beta-Blockade, myopathy, and thyrotoxicosis.

Authors:  M Uusitupa; A Aro; T Korhonen; E Jukka
Journal:  Br Med J       Date:  1980-01-19

Review 3.  Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.

Authors:  P O'Connor; J Feely
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

4.  A study of long acting propranolol in the early management of hyperthyroidism.

Authors:  G R Jones; J H Lazarus; D Wynford-Thomas
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

5.  Duration and selectivity in beta-adrenoceptor blocking action of a beta-adrenoceptor blocking drug, D-32 in conscious dogs.

Authors:  N Himori; S Honma; A Izumi; T Ishimori
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-02       Impact factor: 3.000

6.  Changes in blood chemistry in hypertensive patients during propranolol therapy.

Authors:  F Andreasen; P Jakobsen; H J Kornerup; E B Pedersen; O L Pedersen; J Weeke
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

7.  Effect of timolol on clinical features and echocardiographic assessment of left ventricular function in hyperthyroidism.

Authors:  B E Griffiths; F M Creagh; J H Lazarus; R John; S Kadury
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

8.  Low-dose propranolol for the protection of the left ventricle from ischaemic damage.

Authors:  A H Brown; B L Krause; G M Morritt
Journal:  Thorax       Date:  1981-11       Impact factor: 9.139

9.  Pharmacokinetics of propranolol and sotalol in hyperthyroidism.

Authors:  A Aro; M Anttila; T Korhonen; H Sundquist
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.